Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 16/20 | 0.42 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24820611 | 0.93 | CBLB (0.43) | CBLBWNT1GSK3BDYRK1ASCN10A | |
| SCHEMBL30153114 | 0.93 | CBLB (0.43) | CBLBWNT1GSK3BDYRK1ASCN10A | |
| SCHEMBL24818718 | 0.87 | CBLB (0.47) | CBLB | |
| SCHEMBL24819935 | 0.82 | CBLB (0.47) | CBLB | |
| SCHEMBL30153117 | 0.82 | CBLB (0.47) | CBLB | |
| SCHEMBL30792029 | 0.78 | CBLB (0.44) | CBLBWNT1GSK3BDYRK1A | |
| SCHEMBL30152693 | 0.77 | CBLB (0.40) | CBLBWNT1GSK3BDYRK1A | |
| SCHEMBL24818750 | 0.77 | CBLB (0.45) | CBLBWNT1GSK3BDYRK1A | |
| SCHEMBL24821871 | 0.75 | CBLB (0.37) | CBLB | |
| SCHEMBL30152942 | 0.75 | CBLB (0.37) | CBLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4359381-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CBLB 1/4885WNT1 1763/4885GSK3B 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.